Gilead Sciences (GILD) Q3 2024 Earnings
Gilead Sciences reported Q3 2024 revenue of $7.5B, beat analyst consensus of $7.0B by $529.4M. Diluted EPS came in at $2.02, beat the $1.53 consensus by $0.49. Gilead Sciences reports across 3 business segments, led by Virology, Oncology, and Other Therapeutic Areas.
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about Gilead Sciences's Q3 2024 earnings report.
Gilead Sciences (GILD) reported Q3 2024 earnings on November 6, 2024 after market close.
Gilead Sciences reported revenue of $7.5B and diluted EPS of $2.02 for Q3 2024.
Revenue beat the consensus estimate of $7.0B by $529.4M. EPS beat the consensus estimate of $1.53 by $0.49.
You can read the 10-Q periodic report (0000882095-24-000028) directly on SEC EDGAR. The filing index links above go to sec.gov.